Biogen, Denali Pull Plug on Parkinson’s Program After Mid-Stage Flop

Biogen and Denali Abandon Parkinson's Drug After Phase 2b Failure

Biogen and Denali Therapeutics have decided to discontinue the development of their investigational Parkinson’s disease drug, BIIB122 (DNL151), for idiopathic Parkinson’s. This decision follows the failure of the Phase 2b LUMA trial, which enrolled nearly 650 early-stage Parkinson’s patients. The orally available LRRK2 blocker did not significantly slow disease progression, missing both primary and key secondary endpoints, including disability and impairments in activities of daily living, compared to placebo. Despite this setback, Denali plans to continue the Phase 2a BEACON trial for LRRK2-associated Parkinson’s.

• The Phase 2b LUMA trial, involving nearly 650 patients with early-stage Parkinson’s disease, randomized participants to receive either BIIB122 or placebo. The trial failed to meet its primary endpoint of significantly slowing disease progression. Additionally, key secondary endpoints, such as improvements in disability and daily living activities, were also missed, leading to the partners' decision to abandon the asset for idiopathic Parkinson's.
• BIIB122 (DNL151) is an orally available small-molecule blocker of LRRK2, a protein crucial for cell structure and signal transduction, with its dysfunction linked to Parkinson’s disease. While the mechanistic rationale for LRRK2 inhibition in carriers is considered strong, its application in idiopathic Parkinson’s was viewed as more speculative by analysts, contributing to the higher-risk assessment of the LUMA trial.
• Despite the LUMA trial's failure, Denali Therapeutics intends to proceed with the Phase 2a BEACON trial, which specifically evaluates BIIB122 for patients with LRRK2-associated Parkinson’s. Analysts express more optimism for BEACON, citing evidence of target engagement from LUMA data, where BIIB122 achieved over 90% LRRK2 inhibition outside the CNS and about 30% in cerebrospinal fluid. Data from BEACON are anticipated in the first half of 2027.

BIIB122's LUMA Trial: Unpacking the Phase 2b Outcomes

The TEMPO-1 trial represents a landmark Phase 3 study evaluating tavapadon, a selective dopamine D1/D5 receptor partial agonist, in early Parkinson's disease. This double-blind, placebo-controlled trial enrolled 529 participants across 102 sites in 12 countries, randomizing patients 1:1:1 to receive tavapadon 5 mg, tavapadon 15 mg, or placebo over 27 weeks. Both tavapadon doses demonstrated statistically significant and clinically meaningful improvements in the primary endpoint of combined MDS-UPDRS parts II and III scores at week 26, with treatment differences of -11.5 points for the 5 mg dose and -12.1 points for the 15 mg dose compared to placebo (both P<0.001). The safety profile was favorable, with most adverse events being nonserious and mild to moderate in severity, including nausea (25.4%), headache (16.7%), and dizziness (12.7%) as the most common treatment-related events.

Transcranial pulse stimulation (TPS) emerged as a promising non-invasive intervention in an open-label pilot study involving 14 individuals with Parkinson's disease. The treatment protocol consisted of 12 TPS sessions over 4 weeks, targeting motor and symptom-specific cortical regions. The study demonstrated robust efficacy outcomes with UPDRS total scores improving by 9.43 points (p<0.001, Cohen's d=-0.566) and UPDRS Part III motor scores improving by 4.93 points (p<0.001, d=-0.498). Notably, non-motor symptom burden was reduced by 19.14 points (p=0.014), cognitive performance improved with a 7.28-point gain on SCOPA-COG (p<0.001), and quality of life measures showed sustained improvements one month after treatment completion.

The nilotinib trial in dementia with Lewy bodies provided encouraging safety and efficacy data for repurposing this tyrosine kinase inhibitor. This single-center, Phase 2, randomized, double-blind study enrolled 43 participants receiving either nilotinib 200 mg or matching placebo once daily for 6 months. Safety outcomes were particularly noteworthy, with nilotinib demonstrating superior tolerability compared to placebo, including significantly fewer falls (6 vs 21, p=0.006) and fewer total adverse events (37 vs 74, p=0.054). Efficacy measures showed increased CSF homovanillic acid levels (p=0.004), reduced pTau181/Aβ42 ratio (p=0.034), and improved cognitive performance on the Alzheimer's Disease Assessment Scale-cognition 14 by 2.8 points (p=0.037), with MDS-UPDRS Part I cognition scores also showing improvement (p=0.044) compared to placebo.

The LRRK2 Pathway: A Target in Parkinson's Disease

Parkinson's disease pathogenesis involves complex interactions between genetic susceptibility and environmental factors, affecting multiple cellular pathways. Monogenic forms result from mutations in key genes including α-synuclein (SNCA), Parkin (PRKN), UCHL1, PINK1, DJ-1, and LRRK2. These causative and risk genes encode proteins critical for cellular homeostasis, including protein kinases (PINK1, LRRK2, GAK) and proteins involved in phosphorylation signaling pathways. Parkin functions as an ubiquitin protein ligase facilitating degradation of toxic substrates via the ubiquitin-proteasome system, while PINK1 and LRRK2 participate in phosphorylation of substrates essential for various cellular functions. Environmental toxins, particularly MPTP and pesticides like rotenone, can interact with genetic vulnerabilities to trigger disease mechanisms.

The hallmark pathological feature involves abnormal processing and aggregation of α-synuclein protein, leading to formation of Lewy bodies and neurites in affected neurons. α-synuclein misfolding causes mitochondrial dysfunction, proteasomal system disruption, and microtubule destabilization resulting in axonal transport deficits. This protein aggregation process is facilitated by impaired cellular quality control systems, including dysfunction of the ubiquitin-proteasome system and autophagy pathways. Multiple PD-related genes (SNCA, LRRK2, GBA, ATP13A2, VPS35, FBXO7) encode proteins implicated in or affected by autophagy, highlighting the critical role of protein homeostasis in disease pathogenesis.

Mitochondrial dysfunction represents a central pathogenic mechanism, with deficits in mitochondrial function underpinning both sporadic and familial forms of PD. This dysfunction generates oxidative and nitrosative stress, which occurs early in disease progression and exacerbates nigro-striatal degeneration. Dysregulation of kinase signaling pathways, particularly mitogen-activated protein (MAP) and protein kinase B (AKT) pathways, contributes to neuronal death through activation of JNK and p38 signaling cascades. Additional mechanisms include neuroinflammation, excitotoxicity, calcium homeostasis imbalance, synaptic dysfunction, and loss of neurotrophic factors, all contributing to the progressive degeneration of dopaminergic neurons in the substantia nigra.

LRRK2 Inhibition: A Strategic Reassessment in Parkinson's Disease

The recent decision by Biogen and Denali Therapeutics to discontinue the development of BIIB122 (DNL151) for idiopathic Parkinson’s disease (PD) following its Phase 2b LUMA trial failure represents a significant moment for the neurodegenerative drug development landscape. This orally available LRRK2 blocker, once a beacon of hope, did not significantly slow disease progression, missing both primary and key secondary endpoints. This outcome is particularly impactful given the substantial unmet need for disease-modifying treatments in PD.

Existing evidence points to LRRK2 inhibition as a promising therapeutic approach, especially considering LRRK2 mutations are linked to both familial and sporadic forms of PD. Early clinical studies for BIIB122 had shown encouraging signs, demonstrating good tolerability, substantial peripheral LRRK2 kinase inhibition, modulation of lysosomal pathways, and evidence of CNS distribution and target inhibition. The disconnect between these promising early-phase biomarker data and the lack of clinical efficacy in a larger, unselected idiopathic PD population underscores a critical challenge in drug development for complex neurological disorders.

This setback will undoubtedly prompt a strategic reassessment within the LRRK2 inhibitor space. Denali's decision to continue the Phase 2a BEACON trial for LRRK2-associated Parkinson’s disease is a telling move, suggesting a pivot towards a more targeted, precision medicine approach. This shift acknowledges that while LRRK2 is a validated target, its inhibition may yield more discernible benefits in patients with a direct genetic link to LRRK2 dysfunction. The broader LRRK2 inhibitor class faces increased scrutiny, reinforcing the need for robust clinical validation beyond biomarker modulation. The historical challenges in optimizing LRRK2 inhibitors for CNS penetration, selectivity, and safety, including concerns about potential target-related adverse effects, remain pertinent considerations for future development efforts. Ultimately, this event highlights the arduous path to developing effective disease-modifying therapies for PD, emphasizing the need for refined patient selection and a deeper understanding of disease heterogeneity.